利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

81 条记录 (耗时 0.034 秒)

    Eye therapy system
    61.
    发明授权
    Eye therapy system 失效
    眼科治疗系统

    公开(公告)号：US08398628B2

    公开(公告)日：2013-03-19

    申请号：US12562625

    申请日：2009-09-18

    申请人： David Muller

    发明人： David Muller

    IPC分类号： A61B18/12

    CPC分类号： A61F9/013 ,  A61B18/1815 ,  A61B2018/00011 ,  A61F9/0079 ,  A61F9/009

    摘要： The cornea is reshaped in multiple steps according to varying amounts of energy in varying patterns and/or at varying locations to achieve a customized reshaping of the cornea to address the specific needs of an individual patient. The varying amounts of energy may be applied via one or more conducting elements, which include an outer conductor and an inner conductor disposed within the outer conductor, a distal end of the outer conductor and the inner conductor defining the varying patterns. For example, one step may form a substantially circular lesion to flatten a first portion of the cornea to treat presbyopia, while another step may form a substantially circular and concentric lesion having a greater diameter to steepen a second portion of the cornea to treat hyperopia. Advantageously, continuous transitional regions are formed relative to the reshaped portions to provide vision for intermediate distances.

    摘要翻译： 根据不同模式和/或在不同位置处的不同量的能量，角膜重新成形，以实现角膜的定制重塑以满足个体患者的特定需要。 可以经由一个或多个导电元件施加不同量的能量，所述导电元件包括​​设置在外导体内的外导体和内导体，外导体的远端和限定变化图案的内导体。 例如，一个步骤可以形成基本圆形的损伤，以使角膜的第一部分平坦化以治疗老花眼，而另一步骤可以形成具有较大直径的基本圆形且同心的病变，以使角膜的第二部分陡峭以治疗远视。 有利地，相对于重新成形的部分形成连续的过渡区域以提供中间距离的视觉。

    Method for making structural changes in corneal fibrils
    62.
    发明授权
    Method for making structural changes in corneal fibrils 失效
    角膜原纤维结构变化的方法

    公开(公告)号：US08366689B2

    公开(公告)日：2013-02-05

    申请号：US12570959

    申请日：2009-09-30

    申请人： John Marshall ,  Ali Hussein ,  David Muller

    发明人： John Marshall ,  Ali Hussein ,  David Muller

    IPC分类号： A61M35/00 ,  A61B18/18

    CPC分类号： A61F9/008 ,  A61F9/0079 ,  A61F9/009 ,  A61F2009/00853 ,  A61F2009/00872

    摘要： In a system for stabilizing a pattern of structural changes in corneal fibrils, an eye treatment system causes corneal fibrils of a cornea of an eye to transition from a first structure to a second structure. An application device applies a cross-linking element to the corneal fibrils. An activating device applies an initiating element to the corneal fibrils and activates the cross-linking element. The cross-linking element causes cross-linking in the corneal fibrils to preserve the second structure of the corneal fibrils. Another application device may apply a cross-linking breaker to the corneal fibrils. The cross-linking breaker halts or reverses at least partially the cross-linking in the corneal fibrils. Another activating device applies an initiating element to the corneal fibrils and activates the cross-linking breaker. Advantageously, the cross-linking breaker provides greater control over the amount and progress of cross-linking that occurs in the corneal fibrils.

    摘要翻译： 在用于稳定角膜原纤维结构变化的模式的系统中，眼睛治疗系统使眼睛角膜的角膜原纤维从第一结构转变到第二结构。 应用装置将交联元件应用于角膜原纤维。 激活装置将起始元件施加到角膜原纤维并激活交联元件。 交联元件引起角膜原纤维中的交联以保留角膜原纤维的第二结构。 另一应用装置可以将交联断路器应用于角膜原纤维。 交联断路器至少部分地停止或逆转角膜原纤维中的交联。 另一激活装置将起始元件施加到角膜原纤维并激活交联断路器。 有利地，交联断路器对角膜原纤维中发生的交联的量和进展提供更大的控制。

    SYSTEMS AND METHODS FOR RESHAPING AN EYE FEATURE
    64.
    发明申请
    SYSTEMS AND METHODS FOR RESHAPING AN EYE FEATURE 有权
    用于修复眼睛特征的系统和方法

    公开(公告)号：US20120303008A1

    公开(公告)日：2012-11-29

    申请号：US13480127

    申请日：2012-05-24

    申请人： David Muller ,  Vance Thompson

    发明人： David Muller ,  Vance Thompson

    IPC分类号： A61F9/01 ,  A61F9/007

    CPC分类号： A61F9/013 ,  A61F9/00804 ,  A61F9/00836 ,  A61F2009/00853 ,  A61F2009/00872

    摘要： Systems and methods include a cutting instrument that creates incisions in selected areas of the cornea; an eye therapy system that applies reshaping forces to the cornea; and a controller that determines the selected areas of the cornea for the incisions and the reshaping forces from the eye therapy system, such that the reshaping forces and the incisions combine to achieve corrective reshaping of the cornea. Other systems and methods include measuring an eye to determine a required amount of reshaping of a cornea; determining one or more doses of cross-linking agent and one or more corresponding doses of photoactivating light according to the required amount of reshaping; applying the cross-linking agent to the cornea; and delivering, from a light source, the photoactivating light to the area of the eye, the photoactivating light combining with the cross-linking agent to induce the corrective reshaping of the cornea.

    摘要翻译： 系统和方法包括在角膜的选定区域中产生切口的切割工具; 一种将矫正力应用于角膜的眼科治疗系统; 以及控制器，其确定角膜的选择区域用于切口和来自眼部治疗系统的重塑力，使得重塑力和切口结合以实现角膜的矫正重塑。 其他系统和方法包括测量眼睛以确定角膜重塑的所需量; 根据所需的重塑量确定一种或多种剂量的交联剂和一种或多种相应剂量的光活化光; 将交联剂施用于角膜; 以及从光源将光活化光输送到眼睛的区域，所述光活化光与交联剂结合以引起角膜的矫正重塑。

    STERILIZING APPLICATION OF CROSS-LINKING AGENT
    65.
    发明申请
    STERILIZING APPLICATION OF CROSS-LINKING AGENT 审中-公开
    消毒交联剂的应用灭菌

    公开(公告)号：US20120283621A1

    公开(公告)日：2012-11-08

    申请号：US13468760

    申请日：2012-05-10

    申请人： David Muller

    发明人： David Muller

    IPC分类号： A61M37/00

    CPC分类号： A61F9/008 ,  A61B3/107 ,  A61F9/0079 ,  A61F2009/00844 ,  A61F2009/00857 ,  A61F2009/00872 ,  A61N5/062

    摘要： A method for treating an eye includes applying, to an outer protective layer of an area of an eye, one or more initial doses of a cross-linking agent that acts as a photosensitizer. The method also includes delivering, from a light source, one or more initial doses of ultraviolet light to the area of the eye. The cross-linking agent increases absorption of the ultraviolet light by the area of the eye, and the absorption of the ultraviolet light sterilizes the area of the eye before the outer protective layer is penetrated. Additionally, the method includes penetrating the outer protective layer of the eye to provide access to an area below the outer protective layer. Moreover, the method includes applying a treatment to the eye via the access provided by cutting the outer protective layer. In some embodiments, the cross-linking agent is Riboflavin, and the treatment is LASIK surgery.

    摘要翻译： 用于治疗眼睛的方法包括将一种或多种初始剂量的用作光敏剂的交联剂施加到眼睛区域的外部保护层。 该方法还包括从光源将一个或多个初始剂量的紫外光输送到眼睛的区域。 交联剂通过眼睛的面积增加紫外线的吸收，并且紫外线的吸收在外部保护层被穿透之前对眼睛的区域进行消毒。 此外，该方法包括穿透眼睛的外保护层以提供对外保护层下方的区域的通路。 此外，该方法包括通过切割外部保护层提供的接近对眼睛进行治疗。 在一些实施方案中，交联剂是核黄素，治疗是LASIK手术。

    Determining site-to-site pacing delay for multi-site anti-tachycardia pacing
    68.
    发明授权
    Determining site-to-site pacing delay for multi-site anti-tachycardia pacing 有权
    确定多站点抗心动过速起搏的站点到站点起搏延迟

    公开(公告)号：US08010194B2

    公开(公告)日：2011-08-30

    申请号：US12416778

    申请日：2009-04-01

    申请人： David Muller

    发明人： David Muller

    IPC分类号： A61N1/00

    CPC分类号： A61N1/368 ,  A61B5/0452 ,  A61N1/3682 ,  A61N1/3684

    摘要： An exemplary method includes delivering a pace using an electrode positioned on the lateral wall of the left ventricle of a heart, sensing the pace using an electrode positioned in the right ventricle of the heart, determining a left to right directional conduction time (TLR), delivering a pace using an electrode positioned in the right ventricle of the heart, sensing the pace using an electrode positioned on the lateral wall of the left ventricle of the heart, determining a right to left directional conduction time (TRL), calculating a site-to-site offset (VVATP) for multi-site anti-tachycardia pacing based on the left to right directional conduction time and the right to left directional conduction time and instructing an implantable device to deliver multi-site anti-tachycardia pacing using the site-to-site offset (VVATP). Other exemplary methods, devices, systems, etc., are also disclosed.

    摘要翻译： 一种示例性方法包括使用位于心脏左心室侧壁上的电极来传送步速，使用位于心脏右心室的电极来感测步速，确定从左到右的方向传导时间（TLR）， 使用位于心脏右心室中的电极进行步调，使用位于心脏左心室侧壁上的电极感测步速，确定右向左方向传导时间（TRL），计算位置 - 基于从左到右定向导通时间和从右到左定向传导时间的多位点抗心动过速起搏的现场偏移（VVATP），并且指示植入装置使用位置偏移起搏来提供多部位抗心动过速起搏， 站点偏移（VVATP）。 还公开了其它示例性方法，装置，系统等。

    Eye Therapy
    69.
    发明申请
    Eye Therapy 有权
    眼科治疗

    公开(公告)号：US20110118654A1

    公开(公告)日：2011-05-19

    申请号：US12909228

    申请日：2010-10-21

    申请人： David Muller ,  John Marshall ,  Marc D. Friedman

    发明人： David Muller ,  John Marshall ,  Marc D. Friedman

    IPC分类号： A61F9/007

    CPC分类号： A61N5/062 ,  A61F9/0008 ,  A61F9/013 ,  A61K31/14

    摘要： Embodiments apply a cross-linking agent to a region of corneal tissue. The cross-linking agent improves the ability of the corneal tissue to resist undesired structural changes. For example, the cross-linking agent may be Riboflavin or Rose Bengal, and the initiating element may be photoactivating light, such as ultraviolet (UV) light. In these embodiments, the photoactivating light initiates cross-linking activity by irradiating the applied cross-linking agent to release reactive oxygen radicals in the corneal tissue. The cross-linking agent acts as a sensitizer to convert O2 into singlet oxygen which causes cross-linking within the corneal tissue. The rate of cross-linking in the cornea is related to the concentration of O2 present when the cross-linking agent is irradiated with photoactivating light. Accordingly, the embodiments control the concentration of O2 during irradiation to increase or decrease the rate of cross-linking and achieve a desired amount of cross-linking.

    摘要翻译： 实施例将交联剂应用于角膜组织的区域。 交联剂改善了角膜组织抵抗不良结构变化的能力。 例如，交联剂可以是核黄素或玫瑰红，并且起始元件可以是光活化的光，例如紫外（UV）光。 在这些实施方案中，光活化光通过照射施加的交联剂以释放角膜组织中的活性氧自由基引发交联活性。 交联剂作为敏化剂将O 2转化成单线态氧，导致角膜组织内的交联。 角膜中的交联速率与交联剂用光活化光照射时存在的O 2浓度有关。 因此，实施例控制照射期间的O 2浓度以增加或降低交联速率并达到所需量的交联。